The BREEZE-AD5 study compared baricitinib with placebo to test its efficacy and safety at 1-mg and 2-mg doses.
Based on the results, baricitinib met the primary endpoint, with participants achieving at least a 75% or greater change from baseline in their Eczema Area and Severity Index (EASI) at week 16. Baricitinib also met key secondary endpoints such as clear or almost clear skin.
Price: 144.25, Change: -1.26, Percent Change: -0.87
|Greenbrier Companies' 2021 Earnings Projection Lowered|
|Earnings Estimate Reduced for GCP Applied Technologi...|
|2020 and 2021 Earnings Estimates for Forward Air Dec...|
|2021 Earnings Projection for HB Fuller Reduced|
|2020 Estimate for TechnipFMC Increased but 2021 Earn...|